Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.57 |
| ▸ | CDK1 | P06493 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426575 | 0.84 | IKBKB (0.67) | IKBKBHRH4CDK1CDK2CHUK | |
| Hydrochloric Acid SCHEMBL5428605 | 0.83 | IKBKB (0.60) | IKBKBCDK1CDK2CHUK | |
| SCHEMBL5437759 | 0.82 | IKBKB (0.67) | IKBKBHRH4CDK1CDK2CHUK | |
| SCHEMBL27673989 | 0.81 | HRH4 (0.55) | IKBKBHRH4CDK1CDK2HRH3 | |
| SCHEMBL5425642 | 0.79 | IKBKB (0.50) | IKBKBHRH4CDK1CDK2CHUK | |
| SCHEMBL6981381 | 0.78 | HRH4 (0.62) | HRH4CDK1CDK2HSP90AA1HRH3 | |
| Hydrochloric Acid SCHEMBL5432132 | 0.76 | CDK1 (0.64) | IKBKBHRH4CDK1CDK2HRH3 | |
| SCHEMBL14491957 | 0.74 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL6979605 | 0.73 | DRD2 (0.59) | IKBKBHRH4CDK1CDK2HSP90AA1 | |
| SCHEMBL5418958 | 0.72 | IKBKB (0.69) | IKBKBCDK1CDK2CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | claimed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | claimed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | IKBKB 10/4885HRH4 772/4885CDK1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.